iLite® CD20 (+) Target
BM5010
Optimized for functional assays involving CD20-targeting antibodies, this iLite® target cell expresses CD20 for use in ADCC bioassays.
- "Assay-ready" format for rapid and convenient use
- Reproducible and biologically relevant results
- Reduced assay variability and higher reproducibility compared to cells in culture
Product Overview
iLite® Target CD20 (+) Assay Ready Cells are designed to enable determination of the ADCC and ADCP activity of existing or new anti-CD20 drug candidates.
iLite Target CD20 (+) Assay Ready Cells are based on a human B lymphocyte cell line, Raji (ATCC# CCL-86), and have been genetically engineered and optimized to express high and constant levels of the surface antigen CD20.
The cells are to be use as target cells for measuring the ADCC and ADCP activity of anti-CD20 antibodies and are optimized to give high sensitivity and specificity when used together with iLite ADCC and ADCP Effector Assay Ready Cells.
FOR RESEARCH USE ONLY
How it works
Principle of iLite® ADCC and ADCP Bioassays
Our two-cell ADCC or ADCP bioassays consist of target cells expressing the antigen under study and effector cells closely resembling the natural FcγRIIIa (for ADCC) or FcγRIIa (for ADCP) signal transduction pathway. Target control cells that do not express the antigen are also available. The effector cells contain two luciferase genes: an inducible Firefly luciferase gene and a constitutively expressed Renilla luciferase gene used for control purposes.
What's in the box?
>250 µL of iLite® Assay Ready Cells suspended in cryoprotective medium from Gibco (cat no 12648-010).
Specifications
| Product code | BM5010 |
| Assay target | ADCC ADCP CD20 |
| Size | 1 vial corresponding to one 96 well plate |
| Technology | Cell-based reporter gene assay |
| Detection system | Luminescence |
| Regulatory status | Research Use Only |
Documents
Application Note
